Dr. Atkins Discusses the IMmotion150 Trial in RCC

Michael B. Atkins, MD
Published Online: Friday, Jun 16, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma (RCC).

VEGF inhibitors are a predominant treatment approach in RCC, but there are data that suggest that VEGF may inhibit the immune system in the tumor microenvironment. Atkins says that this sparked interest in exploring combinations with checkpoint inhibitors in this disease.

The IMmotion150 trial randomized patients to either atezolizumab (Tecentriq) alone, atezolizumab plus bevacizumab (Avastin), or sunitinib (Sutent).
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the IMmotion150 trial in renal cell carcinoma (RCC).

VEGF inhibitors are a predominant treatment approach in RCC, but there are data that suggest that VEGF may inhibit the immune system in the tumor microenvironment. Atkins says that this sparked interest in exploring combinations with checkpoint inhibitors in this disease.

The IMmotion150 trial randomized patients to either atezolizumab (Tecentriq) alone, atezolizumab plus bevacizumab (Avastin), or sunitinib (Sutent).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Community Practice Connections™: The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to BedsideDec 29, 20171.5
Publication Bottom Border
Border Publication
x